Salubris Biotherapeutics Secures $35 Million Investment and Unveils Pipeline Advancements

CAR-T Digest - August 2020

22 Apr 2024: Salubris Biotherapeutics Secures $35 Million Investment and Unveils Pipeline Advancements

Salubris Biotherapeutics, Inc. secured $35 million in new funding for ongoing research and development
Clinical trial application filed for JK06, SalubrisBio’s first-in-class biparatopic ADC
JK06 shows low picomolar affinity and robust internalization of the target, with a promising risk:benefit profile in non-clinical studies
First patient enrolled in RENEU-HF, the Phase 2 clinical trial of JK07 in heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF)
JK08, an investigational IL15-CTLA4 antibody fusion for solid tumors, is progressing in Phase 1b/2 trials with encouraging early data
This reflects the company’s dedication to innovation and global growth while maintaining its core mission of developing therapeutics for sizable patient populations with pressing unmet needs